Phase 4
Completed N=29
Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)
Source: ClinicalTrials.gov NCT00832390 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jul 2009
Primary outcomePrimary: Change From Baseline in A1C at Week 24 — -0.2; -1.0; 0.0 Percent Difference
Summary
After 24 weeks of treatment evaluate the efficacy and security.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in A1C at Week 24 |
-0.2; -1.0; 0.0 | — |
Eligibility Criteria
Inclusion Criteria
- Patients Being Treated With Metformin
- Patients With Hba1c Between 6.5 % And 12.0%.
- Type 2 DM
Data sourced from ClinicalTrials.gov (NCT00832390). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.